2023 - Research.com Medicine in Germany Leader Award
Wolfgang Wick integrates several fields in his works, including Immune system and Tumor microenvironment. While working in this field, Wolfgang Wick studies both Tumor microenvironment and Immune system. His Immunology study frequently links to other fields, such as Autoimmunity. His research links Immunology with Autoimmunity. In his research, he undertakes multidisciplinary study on Antigen and Dendritic cell. He undertakes multidisciplinary studies into Dendritic cell and Antigen presentation in his work. He integrates Antigen presentation and T cell in his studies. Wolfgang Wick merges T cell with Antigen in his research. His work in Glioma is not limited to one particular discipline; it also encompasses Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy.
Journal of Clinical Oncology (2010)
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot;Wolfgang Wick;Warren Mason;Roger Henriksson.
The New England Journal of Medicine (2014)
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Dominik Sturm;Hendrik Witt;Hendrik Witt;Volker Hovestadt;Dong Anh Khuong-Quang.
Cancer Cell (2012)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz;Ulrike M. Litzenburger;Ulrike M. Litzenburger;Felix Sahm;Martina Ott.
DNA methylation-based classification of central nervous system tumours
David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt.
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Christian Hartmann;Christian Hartmann;Jochen Meyer;Jörg Balss;David Capper.
Acta Neuropathologica (2009)
Identifying the Best Machine Learning Algorithms for Brain Tumor Segmentation, Progression Assessment, and Overall Survival Prediction in the BRATS Challenge
Spyridon Bakas;Mauricio Reyes;Andras Jakab;Stefan Bauer.
arXiv: Computer Vision and Pattern Recognition (2018)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick;Michael Platten;Christoph Meisner;Joerg Felsberg.
Lancet Oncology (2012)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge.
Lancet Oncology (2014)
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
Simone Fulda;Wolfgang Wick;Michael Weller;Klaus Michael Debatin;Klaus Michael Debatin.
Nature Medicine (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: